Recent Updates — PRTO

Protara Therapeutics reported a net loss of $21.7 million, or $0.35 per share, for the third quarter ended September 30, 2026, compared to a $13.3 million loss in the prior-year period. Research and development expenses rose to $16.8 million from $9.6 million, driven by higher clinical trial costs and personnel-related expenses. The company holds approximately $143 million in cash and investments, sufficient to fund operations into 2028. Additionally, Protara entered an asset purchase agreement with Novex Innovations for TARA-002 manufacturing assets for $8.75 million to bring production capabilities in-house. Protara is a clinical-stage biotechnology company developing therapies for cancer and rare diseases.

Protara Therapeutics, Inc. announced the resignation of Chief Medical Officer Leonardo Viana Nicacio, M.D., effective June 26, 2026. Dr. Nicacio is leaving to pursue other opportunities. His responsibilities will be assumed by Carla Beckham, M.D., the Lead Medical Director and Head of Clinical Development, with ongoing oversight from Jacqueline Zummo, Ph.D., the Chief Research & Development Officer. Protara Therapeutics is a biotechnology company focused on developing therapies for patients with unmet medical needs.

Protara Therapeutics, Inc. held its Annual Meeting of Stockholders on June 12, 2026. Shareholders elected Jesse Shefferman, Barry Flannelly, and Cynthia Smith as Class III directors. The meeting resulted in the ratification of Ernst and Young LLP as the independent registered public accounting firm for the 2026 fiscal year. Stockholders approved an amendment to the 2024 Equity Incentive Plan and an amendment to the Certificate of Incorporation to increase authorized common stock from 100,000,000 to 200,000,000 shares. Additionally, an amendment allowing officer exculpation was approved. Advisory votes regarding executive compensation and the frequency of say-on-pay votes were also conducted. Protara Therapeutics, Inc. is a biotechnology company.